A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial

Table 2 ANC recovery in Induction 1 and Consolidation

	Pegfilgrastim 6 mg (n = 42)	Filgrastim 5 μg/kg/day (n = 41)
Induction 1
Number of patients starting cycle	42	41
Number of patients (%) with SN	42 (100%)	41 (100%)
Number of patients (%) with ANC recovery^a	35 (83%)	32 (78%)
Median time to ANC recovery^b	22 days	22 days
Range	16, 55	19, 62
Difference between medians (95% CI)	0.0 (-1.9 to 1.9)
Consolidation
Number of patients starting cycle	22	24
Number of patients (%) with SN	20 (91%)	21 (88%)
Number of patients (%) with ANC recovery^a	18 (82%)	23 (96%)
Median time to ANC recovery^b	17 days	16.5 days
Range	1, 57	1, 51
Difference between medians (95% CI)	0.5 (-1.1 to 2.1)

ANC, absolute neutrophil count; SN, severe neutropenia (ANC <0.5 × 10⁹/L); CI, confidence interval.
^aIncludes patients whose ANC remained at or above 0.5 × 10⁹/L
^bNumber of days from start of chemotherapy until the first of 2 consecutive days with ANC ≥ 0.5 × 10⁹/L; time to recovery was set to 1 day for patients whose ANC remained at or above 0.5 × 10⁹/L

ISSN: 1471-2407